MAPT and Alzheimer disease: For each group (ie, Aβ-positive CU, Aβ-positive MCI, and AD dementia), sample size reductions for group-level and individualized ROIs were estimated compared with the temporal meta-ROI due to its widespread use with tau PET in the AD field and the best-performing group-level ROI (Figure 4B).